The acute psychotomimetic effect of cannabis is transitory, but evidence indicates that the chronic use, especially if started in adolescence, contributes to the occurrence of schizophrenia.
José Alexandre Crippa, MD, PhD
Advertisement
Articles by José Alexandre Crippa, MD, PhD
Drs Zuardi and Crippa discuss the current stage of scientific evidence that supports the use of cannabidiol in schizophrenia, anxiety, and Parkinson disease.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on Psychiatric Times
1
Whatever Happened to Psychopathology?
2
Positive Phase 3 Results: CTx-1301 for the Treatment of Pediatric ADHD
3
How Can Chatbots Be Made Safe for Psychiatric Patients
4
Who Should Avoid Halloween Tricks and Treats?
5
